BioCentury
ARTICLE | Company News

AZ, Sanofi sharing rights to infant RSV prophylaxis

March 3, 2017 5:43 PM UTC

The MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) and the Sanofi Pasteur vaccines unit of Sanofi (Euronext:SAN; NYSE:SNY) said they will share rights to develop and commercialize infant respiratory syncytial virus (RSV) therapeutic MEDI8897. MedImmune is to receive €120 million ($126.9 million) up front from Sanofi, and is eligible for €495 million ($523.6 million) in milestones.

The partners will share costs and profits equally. AZ is to continue development of MEDI8897 until its first approval, and is responsible for manufacturing. Sanofi Pasteur will lead commercialization...

BCIQ Target Profiles

RSV F protein